Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.
about
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceDifferential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis
P2860
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@ast
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@en
type
label
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@ast
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@en
prefLabel
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@ast
Erlotinib has better efficacy ...... ith EGFR-activating mutations.
@en
P2093
P2860
P356
P1476
Erlotinib has better efficacy ...... with EGFR-activating mutations
@en
P2093
Chao-Hua Chiu
Chieh-Hung Wu
Chu-Yun Huang
Chun-Ming Tsai
Jacqueline Whang-Peng
Jen-Fu Shih
Reury-Perng Perng
Shinn-Liang Lai
Wen-Shuo Wu
Yu-Chin Lee
P2860
P304
P356
10.3892/ETM.2011.383
P50
P577
2011-11-16T00:00:00Z